Evidence Map and Meta-Analysis of Ambroxol-Clenbuterol for Pediatric Wheezing in China

227 randomized controlled trials from 2005-2012 were analyzed in this evidence map, with 14 studies included in a meta-analysis. The study by Yongsheng Guo, published in 2026, evaluates the efficacy and safety of a combination oral solution for children with wheezing disorders. Results indicate the therapy improved response rates and reduced symptom duration and hospital stay compared to conventional treatment.

Use Cases

• Analyzing temporal trends in clinical research based on the evidence mapping from 2005 to 2012
• Evaluating treatment efficacy for pediatric wheezing based on meta-analysis of overall and significant response rates
• Assessing safety profiles of drug combinations based on reported adverse event data
• Modeling symptom resolution times based on reported durations for coughing, wheezing, and other clinical signs

Strengths

• Evidence mapping covers 227 randomized controlled trials, providing a broad overview of the research landscape
• Meta-analysis includes 14 studies with specific risk ratios and mean differences for key outcomes
• Study protocol is registered on INPLASY (INPLASY202480121), indicating a structured methodology

Limitations

• All included studies were conducted in China, which may limit the generalizability of findings
• Adverse event reporting was limited and inconsistent, preventing definitive safety conclusions
• The dataset is a 871.8 KB PDF document; column-level data and row counts are not directly accessible

Provenance

Source

Literature search in PubMed, Embase, Cochrane Library, CNKI, Wanfang, and CBM

Collection Method

Systematic review and meta-analysis of randomized controlled trials

Time Range

Studies included from 2005 to a peak in 2012

Freshness

Last updated 2026-04-22 05:34:56

Geography

Most studies conducted in eastern China, particularly Henan Province